CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

doi:10.1182/blood-2013-08-523548

Article

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Blood - 16 Jan 2014

Krupka Christina, Kufer Peter, Kischel Roman, Zugmaier Gerhard, Bögeholz Jan, Köhnke Thomas, Lichtenegger Felix S, Schneider Stephanie, Metzeler Klaus H, Fiegl Michael, Spiekermann Karsten, Baeuerle Patrick A, Hiddemann Wolfgang, Riethmüller Gert, Subklewe Marion

Abstract excerpt

Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging (BiTE) antibody (AMG 330) for its suitability as a therapeutic agent in acute myeloid leukemia (AML). We first assessed CD33 expression levels by flow cytometry and found expression in >99% of patient samples (n = 621). CD33 was highest...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Abstract excerpt

Topics

Related research